Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | G6PD | P11413 | 1/20 | 0.38 |
| ▸ | IDE | P14735 | 1/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | PNMT | P11086 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16019376 | 0.79 | SMN1; SMN2 (0.37) | SMN1; SMN2ALDH1A1LMNAGLA | |
| SCHEMBL16019362 | 0.79 | CCR2 (0.41) | ALDH1A1RAB9A | |
| SCHEMBL16019358 | 0.79 | KDM4E (0.37) | SMN1; SMN2KIF11PTGS2 | |
| SCHEMBL16019377 | 0.78 | ALDH1A1 (0.45) | SMN1; SMN2ALDH1A1LMNAGLAPTGS2 | |
| SCHEMBL16019390 | 0.75 | TDP1 (0.34) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL16019394 | 0.75 | TRPV4 (0.43) | PTGS2 | |
| SCHEMBL16019391 | 0.74 | PTGS2 (0.33) | SMN1; SMN2ALDH1A1LMNAPTGS2 | |
| SCHEMBL14349353 | 0.74 | BCAT2 (0.37) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL12406437 | 0.72 | SMN1; SMN2 (0.41) | SMN1; SMN2KIF11ALDH1A1LMNAENPP2 | |
| SCHEMBL14349351 | 0.71 | ENPP2 (0.48) | SMN1; SMN2KIF11ALDH1A1ENPP2PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9693556-B2 | Herbicidal pyridazinone derivatives | SYNGENTA LIMITED (GB) | 2017-07-04 | — | — | US | disclosed |
| US-9693556-B2 | Herbicidal pyridazinone derivatives | SYNGENTA LIMITED (GB) | 2017-07-04 | — | — | US | disclosed |
| US-20140256546-A1 | HERBICIDAL PYRIDAZINONE DERIVATIVES | SYNGENTA LIMITED (GB) | 2014-09-11 | — | — | US | disclosed |
| US-20140256546-A1 | HERBICIDAL PYRIDAZINONE DERIVATIVES | SYNGENTA LIMITED (GB) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256546-A1 | HERBICIDAL PYRIDAZINONE DERIVATIVES | PRDX6, PRDX1, CBR3 | SMN1; SMN2 4594/4885KIF11 3703/4885ALDH1A1 861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.